The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
10 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,601,086 in first-year total cost, median $299,958.
Most frequent study sections
- Special Emphasis Panel[ZRG1 OTC-R (11)]5
- Special Emphasis Panel[ZRG1 IMST-L (11)]2
- Special Emphasis Panel[ZRG1 CVRS-H (11)]1
- Special Emphasis Panel[ZRG1 DKUS-N (10)]1
- Special Emphasis Panel[ZRG1 OTC-H (13)]1
Most frequent institutions
- ANGION BIOMEDICA CORPORATION1
- CERAMIDE THERAPEUTICS, LLC1
- CHROMOLOGIC, LLC1
- DISCOVERY LABORATORIES, INC.1
- ICAGEN, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Development of Rx100 as Novel Medical Countermeasure for Acute Radiation Syndrome1R43AI118004-01 | KHAN, SAMINA | RXBIO, INC., TN | $297,087 | ZRG1 |
| 2014 | KL4 Surfactant to Mitigate Radiation-Induced Lung Injury2R44AI102308-03 | SEGAL, ROBERT | DISCOVERY LABORATORIES, INC., PA | $999,999 | ZRG1 |
| 2014 | Single-chain antibody countermeasures for the Radiation GI Syndrome1R43AI106283-01A1 | ROTOLO, JIM | CERAMIDE THERAPEUTICS, LLC, NY | $300,000 | ZRG1 |
| 2014 | XRpro Radioactive Cesium Decorporation Agents1R43AI091186-01A1 | WARNER, BENJAMIN P | ICAGEN, INC., NC | $300,000 | ZRG1 |
| 2014 | Senescence-Chips for Radiation Biodosimetry1R43AI106100-01A1 | WANG, DAOJING | NEWOMICS, INC, CA | $299,999 | ZRG1 |
| 2014 | MicroRNA-Based Radiation Biodosimeter (MiRAD)1R43AI108019-01A1 | JACOB, NADUPARAMBIL KORAHROGERS, CLAUDE J. | CHROMOLOGIC, LLC, CA | $299,968 | ZRG1 |
| 2014 | A Therapeutic for Radiation Induced Lung Injury1R43AI110004-01 | PAKA, LATHA | ANGION BIOMEDICA CORPORATION, NY | $299,948 | ZRG1 |
| 2014 | Medical countermeasure after radiation exposure1R43AI107953-01A1 | CASTILLO, GERARDO M. | PHARMAIN CORPORATION, WA | $299,872 | ZRG1 |
| 2014 | A Novel Recombinant Protein for Mitigating Total Body Radiation Injury1R43AI114218-01 | YANG, WENG-LANG | THERASOURCE, LLC, NY | $294,693 | ZRG1 |
| 2014 | Novel therapeutic for hematopoietic stem cell regeneration in bone marrow post my1R43AI109919-01A1 | BAMDAD, CYNTHIA C. | MINERVA BIOTECHNOLOGIES CORPORATION, MA | $209,520 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.